Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography
Unknown statusPhase 3NCT02113540
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
As the effect of statin use before the angiography to prevent contrast induced nephropathy (CIN) is not well-known, the aim of the current study is to assess the effect of atorvastatin on prevention of CIN in patients undergoing coronary angiography.
Study details
- Official title
- Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography
- Conditions
- Contrast Induced Nephropathy
- Interventions
- Drug: Atorvastatin
- Sponsor
- Isfahan University of Medical Sciences
- Start date
- 2012-01
- Primary completion
- 2014-05
- Sex
- All
- Results posted
- No results posted in this snapshot
- Countries
- Iran
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * having chronic stable angina who were referred for coronary angiography * non-pregnant female subjects * no history of diabetes mellitus * no history of renal failure * no history of single kidney * no history of cardiogenic shock * no history of unstable angina * no history of myocardial infarction * no history of hypersensitivity to statins * no history of previous intravascular contrast injection during one month before admission Exclusion Criteria: * glomerular filtration rate (GFR) \<60 * cardiogenic shock
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02113540